CSIMarket Company Name, Ticker, Suppliers, else..
Supernus Pharmaceuticals inc   (NASDAQ: SUPN)
Other Ticker:  
 


 

Supernus Pharmaceuticals inc

SUPN's Financial Statements and Analysis



Supernus Pharmaceuticals inc reported in the third quarter of 2025 net loss per share of $-0.80 compare to earnings per share of $0.69 in the same quarter a year ago a decrease from $0.40 eps realized in II. Quarter (Jun 30 2025).


third quarter of 2025
Earnings Per Share Revenues
$ -0.8 $  192 Mill
$-1.49     $+16M     +9.34 %



Supernus Pharmaceuticals Inc 's Revenue rose by 9.34 % in third quarter of 2025 (Sep 30 2025) year on year, to $192 million and advanced by 16.11 % sequentially.


Supernus Pharmaceuticals Inc is

More on SUPN's Income Statement



Supernus Pharmaceuticals Inc in the third quarter of 2025 recorded net loss of $-45.117 million, compare to net income of $38.497 million achieved in III. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $22.499 million in the previous quarter.

More on SUPN's Growth

Supernus Pharmaceuticals Inc Inventories
SUPN's Cash flow In the third quarter of 2025 company's net cash flow was $8 million, capital expenditures grew by -0.2-35.50%, to $0 millions compare to same quarter a year ago

More on SUPN's Cash flow Statement


Supernus Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Supernus Pharmaceuticals inc earned $ 1.27 cash per share, on a free-cash flow basis .

Book value fell by -1.18 % sequentially to $18.56 per share, -64.21% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.43 per share from $ 8.22.

Company repurchased 0.09 million shares or 0.16 % in Sep 30 2025.


• More on SUPN's Dividends

 Market Capitalization (Millions) 2,545
 Shares Outstanding (Millions) 57
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 682
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 121
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 652




Supernus Pharmaceuticals inc does not pay out common stock dividend.

In trailing twelve-month period Supernus Pharmaceuticals inc had $ 1.27 cash flow per share, on a free-cash flow basis .

Book value fell by -1.18 % sequentially to $18.56 per share, -64.21% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.43 per share from $ 8.22.

Company repurchased 0.09 million shares or 0.16 % in Sep 30 2025.


• More on SUPN's Balance Sheets

 Market Capitalization (Millions) 2,545
 Shares Outstanding (Millions) 57
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 682
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 121
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 652
   


  News about Supernus Pharmaceuticals inc Earnings

Thriving Sales Bathe Supernus Pharmaceuticals Inc. as Deficit Woe Takes a Backseat in July to September 2023



Supernus Pharmaceuticals Inc, a biopharmaceutical company specializing in central nervous system (CNS) disease treatments, recently released its financial results for the July to September 2023 period. While the numbers paint a concerning picture, it is essential to analyze the implications of these results and understand how they might shape the company's future.
A Widening Deficit:
One of the primary concerns highlighted in the financial report is Supernus Pharmaceuticals Inc's growing deficit. The company reported a deficit per stock of $-0.29, a notable decline from the positive $0.03 reported a year ago. Additionally, the deficit surged further from $-0.02 per share from the previous f...

Supernus Pharmaceuticals Inc reports resilient revenue decline during Q2 2023 earnings season



Supernus Pharmaceuticals Inc, a leading pharmaceutical company, recently released its financial report for the second quarter of 2023. The report highlights a decline in business, resulting in increased losses for the company during this period. Furthermore, revenue experienced a significant decrease compared to the previous year, reflecting various challenges faced by Supernus Pharmaceuticals in the current market.
Financial Analysis:
In the second quarter of 2023, Supernus Pharmaceuticals recorded a loss per share of $-0.02, contrasting with the previous year's figure of $0.14. This decline reflects the challenging market conditions faced by the company, ultimately impacting its financial...

Tax Benefit Boosts Earnings by $7.93 Million: Supernus Pharmaceuticals Inc Shines Amidst Challenging Financial Climate

While Supernus Pharmaceuticals Inc ma...


Date modified: 2025-11-07T08:22:45+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.